Why the study?
Are CYP2C19 polymorphisms associated with clopidogrel responsiveness in patients undergoing percutaneous coronary intervention?
Population
347 Turkish patients who underwent percutaneous coronary interventions with stent implantation
Design
Cohort
Follow-up
at least 7 days
Authors
Loading...
May inform personalized antiplatelet selection post-PCI; leaves open need for outcome trials before routine genotyping.
Are CYP2C19 polymorphisms associated with clopidogrel responsiveness in patients undergoing percutaneous coronary intervention?
The CYP2C19*2 polymorphism is associated with clopidogrel non-responsiveness, whereas the CYP2C19*17 polymorphism enhances its antiplatelet activity in patients undergoing PCI.
Saydam et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: